- Home
- OVID
as 11-07-2025 4:00pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Upcoming Earnings Alert:
Get ready for potential market movements as Ovid Therapeutics Inc. OVID prepares to release earnings report on 13 Nov 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 117.3M | IPO Year: | 2017 |
| Target Price: | $3.13 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $2.01 | Next Earning Date: | 11-13-2025 |
| Revenue: | $6,651,000 | Revenue Growth: | 1070.95% |
| Revenue Growth (this year): | 1081.8% | Revenue Growth (next year): | -96.87% |
Latest Ovid Therapeutics Inc. News
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
Zacks
5 days ago
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
Zacks
5 days ago
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Insider Monkey
15 days ago
B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data
Zacks
a month ago
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
MT Newswires
a month ago
Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says
Zacks
a month ago
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
MT Newswires
a month ago
Wedbush Adjusts Price Target on Ovid Therapeutics to $5 From $3, Maintains Outperform Rating
Compare OVID vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.